ImageneBio (IMA) Non-Current Debt (2023 - 2024)
ImageneBio (IMA) posted Non-Current Debt of $1.1 million for Q4 2024, up 11.68% sequentially from $950000.0 in Q4 2023, and up 11.68% YoY from $950000.0 in Q1 2024.
ImageneBio (IMA) Non-Current Debt (2023 - 2024) Analysis & Trends
ImageneBio has reported Non-Current Debt for 2 years, with the latest figure at $1.1 million in Q4 2024.
- Quarterly Non-Current Debt rose 11.68% year-over-year to $1.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.1 million (up 11.68% YoY) and the FY2024 annual result came in at $1.1 million, up 11.68% from the prior year.
- Non-Current Debt grew to $1.1 million in Q4 2024 per IMA's latest filing, from $950000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $1.1 million in Q4 2024 and troughed at $852000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 8.96 Bn |
| 10 | ImageneBio | 48.35 Mn | -87.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | 950,000.00 |
| Sep 30, 2023 | 852,000.00 |